Could Glucosamine Affect Dementia Progression? What a New Study Suggests

More than 40 million Americans take glucosamine every year - most of them older adults managing knee pain, hip stiffness, or the slow grind of osteoarthritis. It sits on pharmacy shelves without a prescription, marketed as a natural, safe, and well-tolerated supplement for joint health. For decades, that reputation has gone largely unchallenged.

A study published on June 9, 2026 in the journal Nature Metabolism is now raising questions that no one in the joint supplement industry - or the millions of seniors who rely on it - was quite expecting. Researchers at the University of Florida have found a statistically significant association between glucosamine use and faster progression of Alzheimer's disease and related dementias. The findings do not prove causation. But they are specific, mechanistically grounded, and large enough in scale to demand serious clinical attention.

If you or someone you care for takes glucosamine - particularly alongside a diagnosis of mild cognitive impairment or early dementia - this is a study worth understanding in full.

The Study: What Researchers Found

The University of Florida research team, led by senior author Ramon Sun, PhD, director of the Center for Advanced Spatial Biomolecule Research, used artificial intelligence to analyze deidentified electronic health records from the UF Health system spanning 2012 to 2024. They identified patients diagnosed with either Alzheimer's disease and related dementias (ADRD) or mild cognitive impairment (MCI) - two distinct stages of cognitive decline - and cross-referenced those records with documented glucosamine supplement use.

The dataset was substantial. Researchers analyzed records from 24,000 patients with dementia and 41,000 with mild cognitive impairment. Of these, approximately 8% - representing 1,896 patients with ADRD and 2,750 with MCI - had documented glucosamine use of at least one year following diagnosis.

After controlling for age, sex, and demographics, the results were striking. Glucosamine use was associated with a 25% higher likelihood of progression from mild cognitive impairment to full dementia. Among patients already diagnosed with ADRD, glucosamine use was also associated with a 25% increase in mortality risk - the likelihood of death within a specified timeframe. Notably, no elevated mortality risk was observed in the MCI group, suggesting the impact of glucosamine may scale with the severity of existing neurodegeneration.

These findings did not exist in isolation. The research team combined the health record analysis with advanced imaging studies of human brain tissue from post-mortem Alzheimer's specimens and experiments in mouse models of Alzheimer's disease - triangulating the association from three independent directions.

The Mechanism: Hyperglycosylation and Brain Sugar Chemistry

The most scientifically significant aspect of this study is not the statistical association alone - it is the proposed biological mechanism that gives the association biological plausibility.

Glucosamine is a sugar-related molecule. It is classified as an amino sugar, and because of this chemical identity, it feeds directly into a pathway called glycan biosynthesis - the process by which sugar chains are attached to proteins throughout the body, including in the brain. In healthy brains, this process of glycosylation is tightly regulated. These sugar coatings - called N-glycans - guide newly made proteins into their correct three-dimensional shapes and help them attach to the other proteins they work with.

In Alzheimer's disease, this system breaks down. The N-glycan chains pile up where they do not belong. The proteins underneath them begin to fail, leading to synaptic dysfunction, memory loss, and cell death. This pathological condition is called hyperglycosylation - and the new University of Florida study identifies it as a metabolic driver of Alzheimer's disease, not merely a consequence of it.

The researchers demonstrated, through spatial metabolomics and isotope-tracing studies, that hyperglycosylation in Alzheimer's brains is driven by increased glycan biosynthesis - an active upregulation of the sugar-tagging machinery, not simply a passive accumulation. Glucosamine, as a direct substrate for this pathway, may be adding more fuel to an already overactive process.

The mouse model experiments provided the most direct mechanistic evidence. Blocking the enzyme that produces sugar chains like glucosamine improved dementia symptoms in Alzheimer's mice. Feeding those same mice glucosamine made memory loss measurably worse. Critically, healthy mice given the same glucosamine supplement showed no such effect. This distinction is clinically important: the deleterious effects of glucosamine may not be generalizable to all individuals, but appear to be uniquely positioned to exacerbate metabolic vulnerability in the context of existing neurodegeneration.

In Ramon Sun's own words: "Our results suggest that altered metabolism is a significant contributor to Alzheimer's progression and, in addition, addressing the metabolic defect could be an important complement to approaches focused on Alzheimer's plaques and tangles."

What the Study Does Not Tell Us - Critical Limitations

Responsible interpretation of this research requires an equally clear-eyed look at what it cannot establish.

First and most importantly, this is a retrospective observational study. Researchers looked backward at existing health records rather than running a prospective controlled experiment. Observational studies identify associations - they cannot prove causation. People who chose to take glucosamine may have differed from non-users in ways that statistical adjustment cannot fully account for, including disease severity at the time supplement use began, other supplement or medication interactions, or underlying metabolic conditions.

Second, the health records came from a single hospital system in Florida - a geographically and demographically limited sample. Replication across different populations, ethnicities, and healthcare systems is essential before the findings can be generalized.

Third, the study cannot determine dose or duration thresholds. Whether the risk is associated with short-term use, long-term use, high doses, or specific formulations of glucosamine remains entirely unknown.

Matt Gentry, chair of biochemistry and molecular biology at the University of Florida and a co-author of the study, stated directly: "While it's an association and not proof of causality, it does raise an important clinical question that now deserves much more attention."

The researchers are explicit that answering the causation question would require a randomized controlled trial - a study that administers glucosamine to some patients and not others in a controlled setting. That study has not yet been done.

The Contradiction With Earlier Research

This 2026 Nature Metabolism study does not exist in a vacuum. It sits in apparent tension with a body of earlier research that pointed in the opposite direction - toward glucosamine being potentially protective for brain health in cognitively healthy adults.

A 2023 large-scale prospective cohort study using UK Biobank data and Mendelian randomization analysis found that regular glucosamine use was associated with a 16% lower risk of all-cause dementia, a 17% lower risk of Alzheimer's disease, and a 26% lower risk of vascular dementia over a median follow-up of 8.9 years. A separate 2022 prospective cohort study of nearly 500,000 UK Biobank participants similarly found that habitual glucosamine use was associated with reduced dementia risk, with the effect mediated in part through glucosamine's influence on type 2 diabetes risk.

How can these findings coexist? The answer may lie in a critical distinction that the 2026 study itself highlights: the healthy brain versus the diseased brain. In a neurologically intact brain, glycosylation is tightly regulated. Glucosamine's anti-inflammatory properties - which appear to drive its protective associations in healthy populations - may genuinely confer benefit in people without existing neurodegenerative pathology. But in an Alzheimer's brain, where the glycan biosynthetic machinery is already dysregulated and hyperactive, additional glucosamine substrate may tip an already unstable system further toward dysfunction.

Ramon Sun put it directly: "While glucosamine appears safe and potentially protective for a healthy brain, it may be harmful for a brain that is already experiencing cognitive decline."

This context-dependence is one of the most important nuances in the entire study, and it is frequently lost in media coverage of the findings.

Who Should Be Most Concerned?

Based on the current evidence, the population with the most immediate reason to pay attention to this research is not the general adult population taking glucosamine for joint health. It is specifically:

• Adults diagnosed with mild cognitive impairment (MCI) - the stage of cognitive change that frequently precedes full dementia
• Adults diagnosed with Alzheimer's disease or related dementias who are currently taking glucosamine
• Adults with a strong family history of Alzheimer's disease combined with early subjective memory concerns
• Adults with metabolic risk factors - particularly type 2 diabetes - that may already compromise brain glucose metabolism

For people without cognitive concerns, the existing evidence is not sufficient to recommend stopping glucosamine. For those in the above categories, however, a direct conversation with a healthcare provider about whether to continue glucosamine supplementation is now clinically warranted.

As Ramon Sun noted: "A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse." The message is not alarm for everyone - it is targeted vigilance for a high-risk subgroup that is also, by demographic reality, the group most likely to be taking glucosamine in the first place.

What the Joint-Brain Connection Means for Supplement Strategy

The findings of this study open a broader and clinically important question: for older adults managing both joint health and cognitive health - two of the most prevalent concerns in aging - what does an evidence-based supplement strategy actually look like?

The key insight from this research is that metabolic context matters. A supplement that supports one system may, under specific pathological conditions, affect another. This is not unique to glucosamine - it is a fundamental principle of nutritional biochemistry that becomes increasingly relevant as the body ages and physiological systems become less redundant.

For those navigating this overlap between joint health and cognitive health, several natural compounds deserve attention for their dual relevance.

Hydroxytyrosol - Antioxidant Support for Both Brain and Joints

Hydroxytyrosol, a polyphenol extracted from olive oil and olive leaves, is one of the most extensively researched natural antioxidants with relevance to both neurological and musculoskeletal health. Research published in the International Journal of Molecular Sciences confirms that hydroxytyrosol exerts neuroprotective effects and has been investigated for its potential to prevent cognitive decline in relation to Alzheimer's disease, attributable to its ability to cross the blood-brain barrier, neutralize reactive oxygen species, and reduce neuroinflammation.

A review published in the International Journal of Molecular Sciences found that antioxidants derived from the Mediterranean diet - particularly hydroxytyrosol and resveratrol - appear able to delay and modulate cognitive brain aging processes and decrease the occurrence of neurodegeneration. Crucially, hydroxytyrosol also supports the joint microenvironment through its anti-inflammatory properties and skin barrier effects - making it genuinely relevant to both areas of concern for aging adults. Find out more about hydroxytyrosol's neuroprotective and antioxidant properties in this article on hydroxytyrosol and brain health at Naturem.

Omega-3 Fatty Acids - Resolving Neuroinflammation

Omega-3 fatty acids, particularly DHA (docosahexaenoic acid), are among the most robustly studied nutrients for brain health. DHA is a structural component of neuronal cell membranes, and its concentration in the brain declines with age and with Alzheimer's pathology. Omega-3s support synaptic plasticity, reduce neuroinflammation, and modulate the lipid environment in which Alzheimer's plaques form and propagate. For older adults managing joint inflammation who are also concerned about cognitive trajectory, omega-3s from algal sources represent a supplement with evidence supporting both systems simultaneously - without the mechanistic concern raised by glucosamine's interaction with glycan biosynthesis.

Ginkgo Biloba - Cerebral Circulation and Neuroprotection

Ginkgo biloba has one of the longest clinical research histories of any botanical in the cognitive health space. It improves cerebral blood flow, reduces platelet aggregation in cerebral microcirculation, and exerts antioxidant effects in neural tissue. For those with MCI or early cognitive concerns, Ginkgo biloba is one of the few plant-based ingredients with sufficient human trial data to warrant meaningful clinical consideration.

Poria Cocos - Beta-Amyloid Clearance and Neuroinflammation

Poria cocos, a medicinal fungus used for centuries in traditional Chinese and Vietnamese medicine, contains triterpenoids and polysaccharides that have been shown to inhibit beta-amyloid plaque accumulation - a hallmark pathology of Alzheimer's disease - and reduce neuroinflammatory signaling in brain tissue. Its role in the gut-brain axis is also of emerging research interest, given the growing evidence that microbial dysbiosis contributes to neuroinflammatory cascades in Alzheimer's pathology.

For those seeking a formulated approach to cognitive support that incorporates these evidence-based natural ingredients, the Naturem Memory+ product combines Ginkgo biloba, Poria cocos, Polygonum multiflorum, and hydroxytyrosol in a formula designed to support memory, cerebral circulation, and neuroprotective antioxidant activity. This represents an approach to brain health that does not carry the glycan biosynthesis concerns raised by the glucosamine study.

What Researchers Are Calling for Next

The University of Florida team and outside scientists are aligned on what the next steps need to be. A properly designed randomized controlled trial administering glucosamine versus placebo in patients with MCI or early Alzheimer's is the essential next study. Only that design can establish whether the association is causal and define dose, duration, and population parameters with precision.

Beyond that, the researchers have opened a potentially significant therapeutic avenue: if hyperglycosylation is a metabolic driver of Alzheimer's disease rather than merely a consequence, then pharmacological or nutritional strategies that inhibit glycan biosynthesis may represent a new class of intervention in neurodegeneration. Genetic knockdown of glycan biosynthetic enzymes improved cognitive outcomes in Alzheimer's mice in the study - a finding that points toward future drug development targets. The global glucosamine supplement market was valued at approximately $3.8 billion in 2025 and is projected to reach $6.2 billion by 2033 - meaning the clinical and commercial stakes of resolving this question are considerable.

The Practical Takeaway: A Measured, Evidence-Based Response

This study does not justify panic. It does justify a careful, individualized conversation between patients and their healthcare providers. The following framework reflects what the current evidence most clearly supports:

For cognitively healthy adults taking glucosamine for joint pain: The existing evidence does not yet support stopping glucosamine solely on the basis of this study. The earlier protective associations in cognitively healthy populations remain relevant. Continuing to monitor the literature as replication studies emerge is the appropriate response.

For adults with MCI or early dementia currently taking glucosamine: A discussion with a physician or neurologist about whether to continue glucosamine is now clinically warranted. Given the proposed mechanism and the statistical associations found in this study, caution is reasonable while the evidence base matures.

For all older adults managing both joint health and cognitive health: Exploring evidence-based alternatives for joint support that do not carry the glycan biosynthesis concern - including collagen peptides, Boswellia serrata, and omega-3 fatty acids - is a rational strategy, particularly for those in higher-risk cognitive categories.

For carers and family members of people with Alzheimer's or related dementias: Review all current supplements with a prescribing clinician. Over-the-counter supplements are often not disclosed during medical appointments, and their interactions with both disease biology and prescribed medications can be significant.

Science rarely moves in a single clean direction. The glucosamine-cognition story is still being written, and the final chapter will require randomized trial data that does not yet exist. What this study has done is shift the default assumption - from "safe unless proven otherwise" to "requires careful consideration in neurologically vulnerable populations." For a supplement taken by tens of millions of older adults who are precisely the population most at risk for cognitive decline, that shift in default carries real clinical weight.

The information provided in this article is intended for general educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. It should not be used as a substitute for professional medical guidance from a qualified physician, specialist, or licensed healthcare provider. Always consult your doctor or a qualified health professional before making any changes to your diet, supplement routine, exercise program, or treatment plan